title: Hearing improvement after bevacizumab for neurofibromatosis type 2.
authors.forename: Jian-Sheng
authors.initials: JS
authors.lastname: Diao
authors.forename: Wen-Sen
authors.initials: WS
authors.lastname: Xia
authors.forename: Shu-Zhong
authors.initials: SZ
authors.lastname: Guo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D034381:Hearing Loss / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D016518:Neurofibromatosis 2 / Q000150:complications*; D009464:Neuroma, Acoustic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab